Coronary Artery Disease Pipeline Summary

• The Sleep Apnea Pipeline is advancing rapidly, with several biopharmaceutical companies developing innovative therapies aimed at improving disease control, reducing symptom burden, and addressing unmet patient needs.
• The leading Sleep Apnea Companies include Biotronik Inc., Cordis US Corp, AstraZeneca, Sanofi, Pfizer, Boehringer Ingelheim, Hexun Biosciences Co. Ltd, Novartis Pharmaceuticals, Micell Technologies, Abbott Medical Devices, MedTrace Pharma A/S, MedImmune LLC, and others.

Request to unlock the sample page of the “Sleep Apnea Pipeline”

Key Factors Driving the Growth of the Coronary Artery Disease Pipeline

• Rising Global Burden of Coronary Artery Disease

The increasing prevalence of coronary artery disease, driven by aging populations, obesity, diabetes, hypertension, and sedentary lifestyles, is creating a sustained need for innovative therapies and disease-management approaches.

• Growing Focus on Novel Cardiovascular Therapies

Advances in molecular biology and drug discovery are supporting the development of therapies targeting lipid metabolism, inflammation, thrombosis, vascular dysfunction, and other mechanisms involved in CAD progression.

• Increasing Demand for Secondary Prevention

The continued risk of recurrent cardiovascular events among patients with established Coronary Artery Disease is encouraging research into therapies that can provide improved long-term cardiovascular protection beyond conventional treatment approaches.

• Advances in Precision Medicine and Biomarker-Based Approaches

The identification of cardiovascular biomarkers and patient-specific disease characteristics is supporting more targeted clinical development. Precision medicine approaches may help identify patient populations that are more likely to benefit from emerging Coronary Artery Disease therapies.

• Expanding Clinical Research and Industry Investment

Pharmaceutical and biotechnology companies are increasing investments in cardiovascular drug development, while collaborations, licensing agreements, and clinical research initiatives are contributing to a broader and more diversified CAD pipeline.

DelveInsight’s “Coronary Artery Disease Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Coronary Artery Disease pipeline landscape. It covers the Coronary Artery Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Coronary Artery Disease Therapeutics Assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Coronary Artery Disease Pipeline Understanding

Coronary Artery Disease Overview

Coronary Artery Disease, also known as ischemic heart disease, is a chronic cardiovascular disorder caused by the narrowing or obstruction of the coronary arteries, most commonly due to atherosclerosis. Progressive accumulation of lipid-rich plaques within the arterial wall reduces myocardial blood flow, resulting in an imbalance between oxygen supply and demand. Coronary Artery Disease is the leading cause of morbidity and mortality worldwide and is strongly associated with risk factors including Dyslipidemia, hypertension, diabetes mellitus, smoking, obesity, physical inactivity, advancing age, and family history of premature cardiovascular disease.

Clinical manifestations range from asymptomatic ischemia to stable angina, acute coronary syndromes, heart failure, arrhythmias, and sudden cardiac death. Patients commonly present with exertional chest pain or pressure, dyspnea, fatigue, pain radiating to the arm, neck, jaw, or back, and, in acute events, diaphoresis, nausea, and dizziness.

The pathophysiology of Coronary Artery Disease begins with endothelial dysfunction, which promotes low-density lipoprotein (LDL) cholesterol infiltration into the arterial wall, triggering chronic inflammation, macrophage activation, foam cell formation, and progressive atherosclerotic plaque development. Plaque growth gradually narrows the coronary lumen and limits myocardial perfusion, particularly during increased oxygen demand, while plaque rupture or erosion can precipitate thrombosis and acute myocardial infarction.

Coronary Artery Disease Diagnosis is based on clinical assessment, cardiovascular risk evaluation, and evidence of myocardial ischemia. Initial investigations include electrocardiography, cardiac biomarkers such as high-sensitivity cardiac troponin in suspected acute coronary syndromes, transthoracic echocardiography, and stress testing with exercise ECG or imaging. Coronary computed tomography angiography (CCTA) and invasive coronary angiography remain the principal modalities for defining coronary anatomy and lesion severity, while intravascular ultrasound (IVUS) and optical coherence tomography (OCT) may further characterize plaque morphology.

Management of Coronary Artery Disease aims to relieve symptoms, prevent disease progression, and reduce cardiovascular events through a combination of lifestyle modification, pharmacotherapy, and coronary revascularization when indicated. Lifestyle interventions include smoking cessation, a heart-healthy diet, regular physical activity, weight management, and optimal control of blood pressure, diabetes, and lipid levels. Guideline-directed medical therapy includes antiplatelet agents, high-intensity statins, beta-blockers, ACE inhibitors or ARBs for appropriate patients, calcium channel blockers, nitrates, and newer antianginal agents such as ranolazine when needed.

Patients with significant obstructive disease or refractory symptoms may undergo percutaneous coronary intervention (PCI) with stent implantation or coronary artery bypass grafting (CABG) based on anatomical complexity and clinical characteristics. Long-term follow-up, cardiac rehabilitation, and aggressive management of cardiovascular risk factors are essential to reduce recurrent ischemic events and improve survival.

"Coronary Artery Disease Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces an in-depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development.

In the Coronary Artery Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Coronary Artery Disease clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Explore more insights in the report @ End-Stage Coronary Artery Disease Treatment Market Size

Coronary Artery Disease Pipeline Report Highlights

• The Coronary Artery Disease Companies and academics are working to assess challenges and seek opportunities that could influence Coronary Artery Disease R&D. The Coronary Artery Disease Therapies under development are focused on novel approaches to treat/improve Coronary Artery Disease.

Coronary Artery Disease Emerging Drugs Analysis

This segment of the Coronary Artery Disease pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest Coronary Artery Disease news and press releases.

Coronary Artery Disease Emerging Drugs

• YN001: Beijing Inno Medicine Co., Ltd.

YN001 is an investigational active-target liposomal therapy being developed by Beijing Inno Medicine Co., Ltd. for the treatment of Coronary Artery Disease associated with coronary atherosclerosis. The intravenously administered therapy is designed to selectively target atherosclerotic plaques, enhance cholesterol efflux from macrophages, reduce vascular inflammation, and promote plaque regression and stabilization. YN001 is currently being evaluated in the PURIFY-TIMI 81 Phase IIb, randomized, double-blind, placebo-controlled trial to assess its efficacy and safety in adults with coronary atherosclerosis.

• HeXell-2020: Hexun Biosciences

HeXell-2020 is an investigational allogeneic umbilical cord-derived mesenchymal stem cell (UCMSC) therapy being developed by Hexun Biosciences Co., Ltd. for the treatment of stable Coronary Artery Disease. Administered via intravenous infusion, it is designed to leverage the regenerative, anti-inflammatory, immunomodulatory, and tissue repair properties of mesenchymal stem cells to improve myocardial ischemia and vascular health. HeXell-2020 is currently being evaluated in a Phase I/IIa, open-label, dose-escalation clinical trial assessing its safety, tolerability, optimal dose, and preliminary efficacy in patients with stable CAD.

• RO7763505: Roche

RO7763505 is an oral investigational therapy being developed by Hoffmann-La Roche for the treatment of stable Coronary Artery Disease. The compound is currently being evaluated in a Phase I randomized, double-blind, placebo-controlled study assessing its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers and patients with stable CAD.

For more insights into the report @ Coronary Artery Disease Prevalence

Further product details are provided in the report……..

Coronary Artery Disease Pipeline Therapeutic Assessment

This segment of the Coronary Artery Disease Pipeline Report provides insights about the different Coronary Artery Disease drugs segregated based on the following parameters that define the scope of the report, such as:

Major Coronary Artery Disease Companies

There are approx. 20+ key companies that are developing therapies for Coronary Artery Disease. The Coronary Artery Disease Companies which have their Coronary Artery Disease drug candidates in the mid stage, i.e. Phase II include Beijing Inno Medicine Co., Ltd.

Coronary Artery Disease Phases

DelveInsight’s Coronary Artery Disease Pipeline Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Coronary Artery Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Coronary Artery Disease Molecule Type

Coronary Artery Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Coronary Artery Disease Product Type

Coronary Artery Disease Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Coronary Artery Disease Clinical Trials Activities

The Coronary Artery Disease Pipeline Report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Coronary Artery Disease therapeutic drugs key players involved in developing key drugs.

Coronary Artery Disease Pipeline Development Activities

The Coronary Artery Disease Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronary Artery Disease drugs.

Coronary Artery Disease Pipeline Report Insights

• Coronary Artery Disease Pipeline Analysis
• Coronary Artery Disease Therapeutic Assessment
• Coronary Artery Disease Unmet Needs
• Impact of Coronary Artery Disease Drugs

Coronary Artery Disease Pipeline Report Assessment

• Coronary Artery Disease Pipeline Product Profiles
• Coronary Artery Disease Therapeutic Assessment
• Coronary Artery Disease Pipeline Assessment
• Inactive Coronary Artery Disease Drugs Assessment
• Coronary Artery Disease Unmet Needs

Key Questions Answered in the Coronary Artery Disease Pipeline Report

Current Coronary Artery Disease Treatment Scenario and Emerging Therapies:

• How many companies are developing Coronary Artery Disease drugs?
• How many Coronary Artery Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Coronary Artery Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to coronary artery disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What clinical studies are ongoing for coronary artery disease, and what is their status?
• What are the key designations that have been granted to the Coronary Artery Disease emerging drugs?

Key Coronary Artery Disease Companies

• Beijing Inno Medicine Co., Ltd.
• Hexun Biosciences
• XyloCor Therapeutics, Inc.
• Sirius Therapeutics
• Abcentra
• Novo Nordisk
• Roche
• Verve Therapeutics, Inc
• Cynata Therapeutics
• Suzhou Ribo Life Science

Key Coronary Artery Disease Products

• YN001
• HeXell-2020
• XC001
• SRSD107
• Orticumab
• Ziltivekimab
• RO7763505
• VERVE-102
• Research programme
• RBD1119

Stay updated with us for Recent Articles @ New DelveInsight Blogs